REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
11.07
-0.26 (-2.29%)
Aug 18, 2026, 4:00 PM EDT - Market closed
REGENXBIO Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 174.48 | 170.44 | 83.33 | 90.24 | 112.72 | 470.35 |
| 174.48 | 170.44 | 83.33 | 90.24 | 112.72 | 470.35 | |
Revenue Growth | 12.00% | 104.54% | -7.66% | -19.94% | -76.03% | 204.30% |
Cost of Revenue | 252.91 | 248.6 | 242.09 | 266.48 | 297 | 233.27 |
Gross Profit | -78.42 | -78.16 | -158.76 | -176.24 | -184.27 | 237.08 |
Selling, General & Admin | 85.56 | 82.86 | 76.62 | 87.79 | 85.28 | 79.33 |
Other Operating Expenses | 0.17 | 0.18 | 0.87 | 0.4 | -14.18 | 0.33 |
Operating Expenses | 85.72 | 83.04 | 72.48 | 88.19 | 71.1 | 77.1 |
Operating Income | -164.15 | -161.2 | -231.25 | -264.43 | -255.38 | 159.98 |
Interest Expense | -41.95 | -45.01 | -12.66 | -6.86 | -23.25 | -26.28 |
Interest & Investment Income | 9.66 | 12.33 | 18.9 | 11.34 | 5.73 | 7.54 |
EBT Excluding Unusual Items | -196.43 | -193.88 | -225 | -259.95 | -272.91 | 141.25 |
Merger & Restructuring Charges | - | - | - | -3.7 | - | - |
Asset Writedown | - | - | -2.1 | - | - | - |
Other Unusual Items | - | - | - | - | -7.5 | - |
Pretax Income | -196.43 | -193.88 | -227.1 | -263.65 | -280.41 | 141.25 |
Income Tax Expense | - | - | - | -0.15 | -0.08 | 13.41 |
Net Income | -196.43 | -193.88 | -227.1 | -263.49 | -280.32 | 127.84 |
Net Income to Common | -196.43 | -193.88 | -227.1 | -263.49 | -280.32 | 127.84 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 52 | 52 | 50 | 44 | 43 | 42 |
Shares Outstanding (Diluted) | 52 | 52 | 50 | 44 | 43 | 44 |
Shares Change | 2.03% | 4.17% | 13.21% | 1.35% | -1.73% | 17.79% |
EPS (Basic) | -3.76 | -3.76 | -4.59 | -6.02 | -6.50 | 3.01 |
EPS (Diluted) | -3.77 | -3.76 | -4.59 | -6.02 | -6.50 | 2.91 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -249.67 | -126.38 | -175.56 | -228.37 | -238.21 | 134.7 |
Free Cash Flow Per Share | -4.79 | -2.45 | -3.55 | -5.22 | -5.52 | 3.07 |
Gross Margin | -44.95% | -45.86% | -190.53% | -195.29% | -163.47% | 50.41% |
Operating Margin | -94.08% | -94.58% | -277.51% | -293.02% | -226.55% | 34.01% |
Profit Margin | -112.58% | -113.75% | -272.54% | -291.99% | -248.68% | 27.18% |
Free Cash Flow Margin | -143.09% | -74.15% | -210.69% | -253.06% | -211.32% | 28.64% |
EBITDA | -148.78 | -145.58 | -215.03 | -247.11 | -242.47 | 169.54 |
EBITDA Margin | -85.27% | -85.41% | -258.05% | -273.83% | -215.10% | 36.05% |
D&A For EBITDA | 15.37 | 15.62 | 16.22 | 17.32 | 12.91 | 9.56 |
EBIT | -164.15 | -161.2 | -231.25 | -264.43 | -255.38 | 159.98 |
EBIT Margin | -94.08% | -94.58% | -277.51% | -293.02% | -226.55% | 34.01% |
Effective Tax Rate | - | - | - | - | - | 9.49% |
Revenue as Reported | 174.48 | 170.44 | 83.33 | 90.24 | 112.72 | 470.35 |